Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) issued its quarterly earnings data on Monday, May 15th. The biotechnology company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.10, MarketWatch Earnings reports.
Shares of Bellerophon Therapeutics (NASDAQ BLPH) traded down 1.57% during mid-day trading on Friday, reaching $1.25. 196,854 shares of the company’s stock were exchanged. The company has a 50 day moving average price of $1.39 and a 200-day moving average price of $1.09. Bellerophon Therapeutics has a one year low of $0.43 and a one year high of $2.68. The stock’s market cap is $41.24 million.
TRADEMARK VIOLATION WARNING: “Bellerophon Therapeutics, Inc. (BLPH) Releases Earnings Results, Beats Expectations By $0.10 EPS” was originally published by Markets Daily and is the property of of Markets Daily. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.themarketsdaily.com/2017/06/16/bellerophon-therapeutics-inc-blph-announces-quarterly-earnings-results-beats-estimates-by-0-10-eps-updated-updated-updated.html.
Several institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC boosted its position in Bellerophon Therapeutics by 99.7% in the first quarter. Renaissance Technologies LLC now owns 477,400 shares of the biotechnology company’s stock worth $711,000 after buying an additional 238,300 shares during the last quarter. Vanguard Group Inc. boosted its position in Bellerophon Therapeutics by 647.5% in the first quarter. Vanguard Group Inc. now owns 401,530 shares of the biotechnology company’s stock worth $598,000 after buying an additional 347,811 shares during the last quarter. Geode Capital Management LLC purchased a new position in Bellerophon Therapeutics during the first quarter worth about $190,000. Finally, Goldman Sachs Group Inc. purchased a new position in Bellerophon Therapeutics during the first quarter worth about $125,000. Hedge funds and other institutional investors own 42.51% of the company’s stock.
Several brokerages recently weighed in on BLPH. ValuEngine cut shares of Bellerophon Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, June 10th. Ladenburg Thalmann Financial Services started coverage on shares of Bellerophon Therapeutics in a research note on Monday, April 17th. They issued a “buy” rating and a $4.50 price objective on the stock. Two analysts have rated the stock with a sell rating and three have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $3.75.
About Bellerophon Therapeutics
Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.
Receive News & Ratings for Bellerophon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.